Replies to post #310348 on Avid Bioservices Inc (CDMO)

[biopharm]

I ask again.....how many will be aligned with Peregrine Pharmaceuticals by this conference

http://www.pegsummiteurope.com/PEGS_Europe_Content.aspx?id=159021

Again I wonder....as I see a Xencor many names on the list including Renier (that we know works with Dr Wolchok ) and Stanley and many more .....and who was paying attention to Dr Wolchok and being able to avoid off target TOXICITIES with PS Targeting??






Renier Brentjens, Ph.D., Director, Cellular Therapeutics Centre, Memorial Sloan Kettering Cancer Centre
Dr Renier J. Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). Currently, Dr Brentjens is an associate member on the faculty at MSKCC and an attending physician on the leukemia service. Ongoing pre-clinical and clinical research in the focused on the further development of CAR modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of “armored CAR T cells”.

Stanley R. Riddell, M.D., Professor, Immunology & Clinical Research, Fred Hutchinson Cancer Institute
Dr. Riddell’s research focuses on 1) understanding the roles of distinct T cell subsets in protective immunity to pathogens and tumors and 2) the development and clinical application of adoptive T cell therapies for viral diseases and cancers, including with genetically modified antigen-specific T cells. His early studies demonstrated the potential to augment T cell immunity by the adoptive transfer of antigen-specific T cells and uncovered mechanisms by which virally-infected cells evade immune recognition. These findings provided insights into similar mechanisms that tumors use to escape T cell immunity and that might be therapeutically targeted to improve patient outcomes.

Dr. Riddell’s lab has developed critical techniques for isolation, expansion, genetic modification and reinfusion of therapeutic T cells, and for monitoring patient safety, T cell persistence, migration and function post-infusion. These include state-of-the-art ways to identify the tumor cell “antigens” recognized by T cells. Many are now broadly employed in adoptive immunotherapies for cancer that use natural targeting molecules called T cell receptors (TCRs) or use synthetic TCR- and antibody-related molecules known as chimeric antigen receptors (CARs).